WEAVER GREGORY L — SEC insider filings
SEC reporting owner CIK 1251779. 21 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2021-05-18 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 6 filings — 89,666 shares, $235,885 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 157,497 shares, $632,333 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 107,497 shares @ $5.58 ($599,833) in ATOSSA THERAPEUTICS, INC., filed 2021-07-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | Former EVP, CFO, & Director, Director | 7 | 1 leg · 50,000 sh · $48,500 | 2 legs · 157,497 sh · $632,333 | 13 |
| Altimmune, Inc. (ALT) | Chief Financial Officer | 11 | 4 legs · 35,000 sh · $117,395 | — | 16 |
| ATAI Life Sciences N.V. (ATAI) | Chief Financial Officer | 3 | 1 leg · 4,666 sh · $69,990 | — | 2 |
Insider filings — WEAVER GREGORY L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Altimmune, Inc. (ALT) | Option exercise (M): 18,750 @ $0 · Tax withholding (F): 5,672 @ $1.93 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2026-11-13 | 4 | Altimmune, Inc. (ALT) | Purchase (P): 10,000 @ $1.62 | EDGAR |
| 2026-10-05 | 4 | Altimmune, Inc. (ALT) | Option exercise (M): 14,475 @ $0 · Tax withholding (F): 4,379 @ $2.76 · Option exercise (M): 14,475 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | Altimmune, Inc. (ALT) | Grant/award (A): 1,753 @ $2.41 | EDGAR |
| 2026-04-01 | 4 | Altimmune, Inc. (ALT) | Purchase (P): 10,000 @ $3.15 | EDGAR |
| 2026-03-09 | 4 | Altimmune, Inc. (ALT) | Purchase (P): 5,000 @ $3.54 | EDGAR |
| 2026-02-27 | 4 | Altimmune, Inc. (ALT) | Grant/award (A): 259,000 (derivative) @ $0 · Grant/award (A): 111,000 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | Altimmune, Inc. (ALT) | Option exercise (M): 18,750 @ $0 · Tax withholding (F): 5,672 @ $4.28 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Altimmune, Inc. (ALT) | Grant/award (A): 166,800 (derivative) @ $0 · Grant/award (A): 57,900 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Altimmune, Inc. (ALT) | Purchase (P): 10,000 @ $5.20 | EDGAR |
| 2024-11-12 | 4 | Altimmune, Inc. (ALT) | Grant/award (A): 225,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-11-17 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Sale (S): 50,000 @ $0.65 | EDGAR |
| 2023-06-20 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Purchase (P): 50,000 @ $0.97 | EDGAR |
| 2023-06-05 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 2,600,000 (derivative) @ $0 | EDGAR |
| 2023-05-05 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-05-16 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-03-04 | 4 | ATAI Life Sciences N.V. (ATAI) | Grant/award (A): 228,000 (derivative) @ $0 | EDGAR |
| 2021-07-07 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Option exercise (M): 4,581 @ $5.64 · Option exercise (M): 45,000 @ $2.38 · Option exercise (M): 45,000 @ $2.52 · Option exercise (M): 70,000 @ $1.70 · Tax withholding (F): 57,084 @ $6.40 · Sale (S): 107,497 @ $5.58 · +4 more | EDGAR |
| 2021-06-24 | 4 | ATAI Life Sciences N.V. (ATAI) | Purchase (P): 4,666 @ $15 | EDGAR |
| 2021-06-22 | 4 | ATAI Life Sciences N.V. (ATAI) | Grant/award (A): 67,726 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | ATOSSA THERAPEUTICS, INC. (ATOS) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1251779 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs